Medulloblastoma

Biotin-11-dCTP is a biotinylated deoxynucleoside triphosphate and an important DNA labeling reagent. In random primer DNA labeling reactions, Biotin-11-dCTP incorporates into newly synthesized DNA strands to generate labeled DNA probes suitable for hybridization applications. In addition, Biotin-11-dCTP can serve as a substrate for terminal deoxynucleotidyl transferase to end-label oligonucleotides for telomere sequence detection, or to label the cut ends of linearized DNA molecules, thereby supporting streptavidin-based electron microscopy analysis. For example, Biotin-11-dCTP can label the cut ends of linearized DNA molecules under the action of dGTP and avian myeloblastosis virus reverse transcriptase.

CT-179 is a brain-penetrant and orally active OLIG2 inhibitor with a human IC₅₀ of 1250 nM. CT-179 disrupts OLIG2 dimerization, phosphorylation, and DNA binding, blocking OLIG2-driven transcription. CT-179 induces G₂/M phase arrest and increases G₀ population. CT-179 induces apoptosis by reducing anti-apoptotic proteins and increasing cleaved caspase-3 and cleaved PARP. CT-179 can be used for the research of subgroup medulloblastoma.

SJ995973 is a BRD4 PROTAC degrader with DC₅₀ values of 0.87 nM (12 h) and 0.16 nM (24 h), respectively. SJ995973 induces the formation of a ternary complex between purified BRD4 and CRBN-DDB1 proteins, with an IC₅₀ of 17 nM against CRBN. SJ995973 inhibits the viability of human acute myeloid leukemia cells. SJ995973 can be used in studies related to acute myeloid leukemia and medulloblastoma.

Anti-ITGB1 Antibody (AIIB2) is a monoclonal antibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the ITGB1 subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma.

CJM061 is a WEE1 kinase inhibitor with a target IC₅₀ of 2.8 nM. CJM061 acts as a sensitizer and exhibits synergistic effects with Cisplatin (HY-17394) in medulloblastoma cells. CJM061 can be used for the research of medulloblastoma.

QBS10072S dihydrochloride is a LAT1-selective substrate with blood-brain barrier permeability that inhibits tumor growth. QBS10072S dihydrochloride enters LAT1-expressing tumor cells via LAT1-mediated active transport, induces interstrand DNA cross-linking and cell apoptosis, and reduces leptomeningeal dissemination. QBS10072S dihydrochloride can be used in studies related to glioblastoma multiforme, diffuse intrinsic pontine glioma, triple-negative breast cancer brain metastases, and aggressive T-cell lymphoma.

SJ44236 is a BET PROTAC degrader with activity against BRD2, BRD3 and BRD4 (DC₅₀ = 127 pM). SJ44236 induces ubiquitination and proteasomal degradation by forming a ternary complex with BET proteins and CRBN-DDB1. SJ44236 downregulates c-Myc, upregulates p53 and reduces cancer cell viability. SJ44236 can be used for the research of leukemia and medulloblastoma.